IPC Signs Institutional MoUs to Strengthen Pharmaceutical Quality and Patient Safety Framework

In a major step toward enhancing the quality, safety, and scientific rigor of India’s pharmaceutical ecosystem, the Indian Pharmacopoeia Commission (IPC), under the Ministry of Health and Family Welfare, has signed two strategic Memoranda of Understanding (MoUs) with the Pharmaceuticals & Medical Devices Bureau of India (PMBI) and the National Institute of Pharmaceutical Education and Research (NIPER), Hajipur.

These collaborations mark a significant advancement in India’s efforts to ensure affordable, high-quality medicines, strengthen pharmacovigilance systems, and reinforce its global leadership in pharmaceutical standards and regulatory excellence.

Strengthening Quality Assurance in Jan Aushadhi Medicines

The MoU between IPC and PMBI focuses on enhancing the quality assurance framework for medicines distributed through Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs)—a flagship initiative aimed at providing affordable generic medicines to citizens.

Under this partnership:

• Randomly selected batches of Jan Aushadhi medicines may be submitted to IPC for rigorous quality testing

• The National Formulary of India (NFI) will be promoted across PMBJKs to ensure rational and standardized use of medicines

• Pharmacovigilance systems will be strengthened through wider dissemination of the Pharmacovigilance Programme of India (PvPI)

To enhance patient safety and reporting:

• QR codes linked to PvPI and a toll-free helpline (1800-180-3024) will be displayed at PMBJK outlets nationwide

• Citizens will be encouraged to report Adverse Drug Reactions (ADRs), improving real-time safety monitoring

Additionally, IPC and PMBI will jointly conduct:

• Training and sensitization programmes for pharmacists

• Awareness initiatives on rational drug use and ADR reporting tools

• Capacity-building efforts to enhance the role of pharmacists in public health

Advancing Research and Innovation with NIPER Hajipur

The second MoU between IPC and NIPER Hajipur aims to deepen collaboration in pharmaceutical research, academic exchange, and capacity building, particularly in emerging and high-impact areas of drug development and safety.

NIPER Hajipur, an Institute of National Importance, brings advanced expertise in:

• Pharmaceutical analysis

• Biologics and biosimilars

• Clinical research

Key areas of collaboration include:

• Joint research on impurity profiling, including critical genotoxic impurities such as nitrosamines

• Correlation of impurity data with adverse drug reaction trends to establish evidence-based pharmacopoeial standards

• Development of analytical methods, quality control protocols, and reference standards

The partnership will also focus on next-generation therapeutics, including:

• Biologics and biosimilars

• Cell and gene therapy products

These efforts are expected to strengthen the Indian Pharmacopoeia, ensuring it remains aligned with global scientific advancements.

Building Scientific Capacity and Talent Ecosystem

Both IPC and NIPER Hajipur will collaborate on a wide range of academic and capacity-building initiatives, including:

• Joint training programmes, workshops, and conferences

• Faculty exchange programmes and shared use of advanced laboratory infrastructure

• Internship and fellowship opportunities for pharmacy students and researchers

• Collaborative publication of research papers, training manuals, and educational resources

Such initiatives aim to create a robust pipeline of skilled professionals and foster a culture of innovation in pharmaceutical sciences.

Reinforcing India’s Global Pharmaceutical Leadership

India is already recognized as the “pharmacy of the world,” supplying over 20% of global generic medicines and playing a critical role in ensuring affordable healthcare worldwide. These MoUs further strengthen India’s position by focusing on quality assurance, regulatory science, and innovation.

By integrating quality testing, pharmacovigilance, and advanced research, the collaborations are expected to:

• Enhance patient safety and trust in generic medicines

• Improve regulatory standards and compliance

• Support India’s ambitions in biopharmaceutical and advanced therapy development

A Step Toward a Safer and More Innovative Healthcare System

These agreements reflect IPC’s ongoing commitment to building a patient-centric, science-driven healthcare ecosystem, aligned with the broader national vision of accessible and high-quality healthcare for all.

As India continues to expand its pharmaceutical footprint globally, such institutional collaborations will play a crucial role in ensuring that affordability is matched by uncompromising quality and safety standards.

With a focus on innovation, regulation, and public health, the IPC’s partnerships with PMBI and NIPER Hajipur signal a forward-looking approach—one that strengthens India’s healthcare system while reinforcing its status as a global leader in pharmaceuticals.